Mark Kindy to Alzheimer Disease
This is a "connection" page, showing publications Mark Kindy has written about Alzheimer Disease.
Connection Strength
3.820
-
Effects of GrandFusion Diet on Cognitive Impairment in Transgenic Mouse Model of Alzheimer's Disease. Nutrients. 2020 Dec 30; 13(1).
Score: 0.493
-
GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
Score: 0.433
-
High-Sodium Diet Has Opposing Effects on?Mean Arterial Blood Pressure and?Cerebral Perfusion in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2016 10 04; 54(3):1061-1072.
Score: 0.367
-
Preface. Turk J Med Sci. 2015; 45(5):i-ii.
Score: 0.325
-
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
Score: 0.264
-
The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
Score: 0.246
-
Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
Score: 0.239
-
Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008 May; 172(5):1342-54.
Score: 0.204
-
Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
Score: 0.196
-
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. Pharmacol Rev. 2022 07; 74(3):600-629.
Score: 0.137
-
Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
Score: 0.123
-
CBF regulation in hypertension and Alzheimer's disease. Clin Exp Hypertens. 2020 Oct 02; 42(7):622-639.
Score: 0.118
-
Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
Score: 0.065
-
Targets for AD treatment: conflicting messages from ?-secretase inhibitors. J Neurochem. 2011 May; 117(3):359-74.
Score: 0.062
-
Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
Score: 0.055
-
Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
Score: 0.050
-
Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem. 2007 Feb; 388(2):247-52.
Score: 0.047
-
Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005 Feb 01; 14(3):447-60.
Score: 0.041
-
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004 Oct 13; 23(20):4096-105.
Score: 0.040
-
Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets. 2004 Aug; 5(6):517-28.
Score: 0.039
-
Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci. 2004; 22(1-2):5-11.
Score: 0.038
-
Abeta deposition is essential to AD neuropathology. J Alzheimers Dis. 2002 Jun; 4(3):133-8.
Score: 0.034
-
Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002 Jun; 4(3):145-54.
Score: 0.034
-
Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002 Jan 04; 924(1):90-7.
Score: 0.033
-
Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry. 2001 Feb 27; 40(8):2548-54.
Score: 0.031
-
Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci. 2000 Feb 15; 20(4):1358-64.
Score: 0.029
-
Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology. 1999 Oct 22; 53(7):1391-6.
Score: 0.028
-
Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
Score: 0.019
-
High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008 Jul; 106(1):475-85.
Score: 0.013
-
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003 Mar 15; 23(6):1992-6.
Score: 0.009
-
Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24; 226(3):672-80.
Score: 0.006